Antibiotherapy in Children with Cystic Fibrosis—An Extensive Review

Ciucă, Ioana; Dediu, Mihaela; Popin, Diana; Pop, Liviu; Tamas, L.; Pilut, Ciprian Nicolae; Guta, B. Almajan; Popa, Z.

doi:10.3390/children9081258

Cited by 11 publications

(9 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is the rationale behind the long-term use of aerosolized antibiotics, typically tobramycin and aztreonam, which are advised due to their favorable effects on lung function and are typically used to treat Pseudomonas aeruginosa and the removal of germs. However, due to its antiinflammatory and antibacterial qualities, long-term azithromycin treatment is still advised for young CF patients (26).…”

Section: Cf Treatment Regimensmentioning

confidence: 99%

Cystic fibrosis management in pediatric population—from clinical features to personalized therapy

Azoicai,

Lupu,

Trandafir

et al. 2024

Front. Pediatr.

View full text Add to dashboard Cite

Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations of the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR). In 1949, it's been identified as a monogenic disease and was thought to primarily affect individuals of Northern European descent. It was the most prevalent autosomal recessive disease that shortens life. With the availability of multiple testing methodologies nowadays, there is a chance to create novel and enhanced treatment options. Even in the absence of a high sweat chloride test (SCT) result, the discovery of two causal mutations is diagnostic for cystic fibrosis (CF). For a CF diagnosis, however, at least two positive E sweat chloride tests are still required. In order to achieve early and active intervention to manage cystic fibrosis (CF) and its comorbidities, treatment regimens for pediatric patients should be evaluated, improved, and closely monitored. New developments in the treatment of cystic fibrosis (CF) have led to the development of medications derived from molecules that target the pathogenetic pathway of the illness. These options are very efficient and allow pediatric patients to receive individualized care. However, in order to better direct patient care and enhance patient outcomes, it is crucial to research uncommon CF mutations, which can provide crucial information about the prognosis of the disease and the relationships between genotype and phenotype. To ensure the success of creating novel, safer, and more efficient treatment approaches, a deeper understanding of the pathogeny of the illness is required. In the age of customized medicine, genetic research will be essential to improving patient care and quality of life for those with uncommon mutations.

show abstract

Section: Cf Treatment Regimensmentioning

confidence: 99%

Cystic fibrosis management in pediatric population—from clinical features to personalized therapy

Azoicai,

Lupu,

Trandafir

et al. 2024

Front. Pediatr.

View full text Add to dashboard Cite

show abstract

“…Burkholderia is a genus of Proteobacteria that shows resistance to multiple antibiotic agents [ 66 ]. Some Burkholderia species, including Burkholderia pseudomallei and Burkholderia cepacian , cause serious lethal infectious diseases, such as melioidosis and severe pneumonia in patients with cystic fibrosis [ 67 , 68 ]. On the other hand, Burkholderia species are known to be common environmental contaminants.…”

Section: Challenges In Clinical Diagnosis Of Microbial Ce: What Is Th...mentioning

confidence: 99%

Challenges in Clinical Diagnosis and Management of Chronic Endometritis

Yasuo

Kitaya²

2022

Diagnostics

View full text Add to dashboard Cite

Chronic endometritis (CE) is a local mucosal infectious and inflammatory disorder characterized by unusual filtration of CD138(+) endometrial stromal plasmacytes. CE is attracting attention due to its potential association with infertility of unknown etiology, repeated implantation failure, recurrent pregnancy loss, and several maternal/neonatal complications. Due to the variance in study design among researchers, universal diagnostic criteria remain to be established for the clinical diagnosis and management of CE. This review article aims to summarize current knowledge and provide insights into unsolved questions on CE to establish clinical guidelines for the disease from the viewpoint of human reproduction.

show abstract

“…Despite the development of new antibiotics, especially inhaled ones, the management of infections, particularly of resistant microorganisms, remains a challenge [ 45 ]. Newer cephalosporin combinations like ceftazidime/avibactam and ceftolozane/tazobactam are now available to treat P. aeruginosa , (while ceftaroline is also effective for Gram-positive bacteria, including MRSA [ 45 , 49 ].…”

Section: Future Treatmentsmentioning

confidence: 99%

Inflammation and Infection in Cystic Fibrosis: Update for the Clinician

2022

View full text Add to dashboard Cite

Inflammation and infection play an important role in the pathophysiology of cystic fibrosis, and they are significant causes of morbidity and mortality in CF. The presence of thick mucus in the CF airways predisposes to local hypoxia and promotes infection and inflammation. A vicious cycle of airway obstruction, inflammation, and infection is of critical importance for the progression of the disease, and new data elucidate the different factors that influence it. Recent research has been focused on improving infection and inflammation in addition to correcting the basic gene defect. This review aims to summarize important advances in infection and inflammation as well as the effect of new treatments modulating the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein. New approaches to target infection and inflammation are being studied, including gallium, nitric oxide, and phage therapy for infection, along with retinoids and neutrophil elastase inhibitors for inflammation.

show abstract

Antibiotherapy in Children with Cystic Fibrosis—An Extensive Review

Cited by 11 publications

References 89 publications

Cystic fibrosis management in pediatric population—from clinical features to personalized therapy

Cystic fibrosis management in pediatric population—from clinical features to personalized therapy

Challenges in Clinical Diagnosis and Management of Chronic Endometritis

Inflammation and Infection in Cystic Fibrosis: Update for the Clinician

Contact Info

Product

Resources

About